A Search Service for Abbreviation / Long Form

■ Abbreviation / Long Form : PRSP / penicillin-resistant Streptococcus pneumoniae

[Related PubMed/MEDLINE]
Total Number of Papers: 119
[Display Entries]
100 entries :
     (Publication year, Descending)
100 entries :
     (Publication year, Ascending)
>> all entries
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation:   PRSP  (>> Co-occurring Abbreviation)
Long Form:   penicillin-resistant Streptococcus pneumoniae
 Abbreviation Variation
 Long Form Variation
 Pair(Abbreviation/Long Form) Variation
No. Year Title Co-occurring Abbreviation
2022 Clinical Perspective of Antimicrobial Resistance in Bacteria. AMR, CPE, MDR, MRSA, VRE
2021 In vitro Activity of Contezolid Against Methicillin-Resistant Staphylococcus aureus, Vancomycin-Resistant Enterococcus, and Strains With Linezolid Resistance Genes From China. DAP, FFC, LZD, MRSA, TEC, TGC, VA, VRE
2020 Cell Division Protein FtsZ Is Unfolded for N-Terminal Degradation by Antibiotic-Activated ClpP. ADEP, ADEPs, MRSA
2019 Comparative in vitro potency and kill curve activity of tedizolid and linezolid against Gram-positive bacteria isolated from Chinese hospitalized patients in 2013-2016. MIC, MRSA
2019 Efficacy of educational intervention on reducing the inappropriate use of oral third-generation cephalosporins. BLNAR, DOTs, ESBL-EC, HA-CDI
2019 In vitro activities of Eravacycline against 336 isolates collected from 2012 to 2016 from 11 teaching hospitals in China. ESBL, MRSA, VRE
2018 Antimicrobial susceptibility among gram-positive and gram-negative blood-borne pathogenscollected between 2012-2016 as part of the Tigecycline Evaluation and Surveillance Trial. CLSI, ESBL, FDA, MIC, MRSA, T.E.S.T, VR
2018 Comparison between local and national epidemiology of antimicrobial resistance using the JANIS data. JANIS, MRSA
2018 Design, Synthesis, and Biological Evaluation of Novel 7-[(3 aS,7 aS)-3 a-Aminohexahydropyrano[3,4- c]pyrrol-2(3 H)-yl]-8-methoxyquinolines with Potent Antibacterial Activity against Respiratory Pathogens. hERG, QR- E. coli, QR- MRSA
10  2016 Development and Characterization of Potent Cyclic Acyldepsipeptide Analogues with Increased Antimicrobial Activity. ADEPs
11  2016 Identification of novel aminopiperidine derivatives for antibacterial activity against Gram-positive bacteria. MRSA, PDF, VRE
12  2016 Longitudinal surveillance on antibiogram of important Gram-positive pathogens in Southern China, 2001 to 2015. CNS
13  2016 Novel broad-spectrum and long-acting parenteral cephalosporins having an acyl cyanamide moiety at the C-3 terminal: Synthesis and structure-activity relationships. BLNAR
14  2015 Comparison of inducible versus constitutive expression of plectasin on yields and antimicrobial activities in Pichia pastoris. MIC, MRSA, VREF
15  2014 In vivo antibacterial activity of MRX-I, a new oxazolidinone. MRSA, PISP, VRE
16  2014 Potent oxazolidinone antibacterials with heteroaromatic C-ring substructure. MRSA, VRE
17  2014 [Genetic analysis of multidrug-resistant Streptococcus pneumoniae including meropenem resistance that was isolated from elderly residents with pneumonia in nursing-care facilities]. CC, CTX, MDRSP, MEPM, MLST
18  2013 In vitro and in vivo antibacterial activities of omadacycline, a novel aminomethylcycline. ABSSSI, CABP, H. influenzae, MRSA, UTI, VRE
19  2013 [Morphological changes in penicillin-resistant Streptococcus pneumoniae and beta-lactamase-nonproducing, ampicillin-resistant Haemophilus influenzae after exposure to oral antibacterial agents]. BLNAR, CDTR, TBPM, TFLX
20  2012 Activity of tedizolid phosphate (TR-701) in murine models of infection with penicillin-resistant and penicillin-sensitive Streptococcus pneumoniae. PSSP
21  2012 Antimicrobial resistance trends among 5608 clinical Gram-positive isolates in China: results from the Gram-Positive Cocci Resistance Surveillance program (2005-2010). MICs, MRSA, MRSCoN, VRE
22  2012 Current and future challenges in the development of antimicrobial agents. CREs, ESBL, MRSA, VRE
23  2011 Frequency and clinical course of invasive pneumococcal disease caused by penicillin-resistant and penicillin-sensitive Streptococcus pneumoniae in Thai children. IPD, MIC, PSSP
24  2011 Infection of pacemaker lead by penicillin-resistant Streptococcus Pneumoniae. ---
25  2011 Trends in the susceptibility of clinically important resistant bacteria to tigecycline: results from the Tigecycline In Vitro Surveillance in Taiwan study, 2006 to 2010. ESBL, FDA, MRSA, TIST, VRE
26  2011 [Factor analysis of outcomes during drug-resistant bacterial infection treatment]. IVH, MDRP, MRSA
27  2010 Comparative efficacy of besifloxacin and other fluoroquinolones in a prophylaxis model of penicillin-resistant Streptococcus pneumoniae rabbit endophthalmitis. CFU, PBS
28  2010 Trends in antimicrobial susceptibility of Streptococcus pneumoniae in the Tohoku district of Japan: a longitudinal analysis from 1998 to 2007. PNSP, RTIs
29  2010 Use of linezolid in pediatrics: a critical review. MRSA, VRE
30  2009 Telavancin: a new lipoglycopeptide for gram-positive infections. AUC/MIC, D-Ala-D-Ala, ECG, GISA, MRSA, VRE, VRSA
31  2009 [Efficacy and safety of faropenem in pediatric patients with bacterial infectious diseases]. FRPM, UTI
32  2008 beta-lactams against emerging 'superbugs': progress and pitfalls. MRSA
33  2008 Detection of pbp2b and ermB genes in clinical isolates of Streptococcus pneumoniae. PISP, ply, PSSP, UMMC
34  2008 Epidemics of drug-resistant bacterial infections observed in infectious disease surveillance in Japan, 2001-2005. MDR-PA, MRSA, NESID
35  2008 In vivo pharmacodynamics of ceftobiprole against multiple bacterial pathogens in murine thigh and lung infection models. MRSA, PAEs, PK
36  2008 Prevention and treatment of penicillin-resistant Streptococcus pneumoniae meningitis after intracraniofacial surgery with distraction osteogenesis. ---
37  2008 [Novel gene sequence variants of pbp2b in penicillin-nonsusceptible Streptococcus pneumonia isolates]. MIC, PBP, PNSP
38  2007 A critical review of oxazolidinones: an alternative or replacement for glycopeptides and streptogramins? MRSA, VRE
39  2007 Antibacterial activity and PK/PD of ceftriaxone against penicillin-resistant Streptococcus pneumoniae and beta-lactamase-negative ampicillin-resistant Haemophilus influenzae isolates from patients with community-acquired pneumonia. BLNAR, CAP, CLSI
40  2007 Ceftobiprole - a case study. cSSSIs, HAP, hCAP, MRSA
41  2007 Comparative in vitro activities of carbapenem antimicrobial agents against 264 penicillin-resistant Streptococcus pneumoniae isolates from Korea. ---
42  2007 High prevalence of erythromycin resistance and macrolide-resistance genes, mefA and ermB, in Streptococcus pneumoniae isolates from the upper respiratory tracts of children in the Sapporo district, Japan. PSSP
43  2007 [Efficacy and safety of potassium clavulanate/amoxicillin (CLAVAMOX) dry syrup in children with otitis media]. ADRs, CLAVAMOX, PISP
44  2007 [Efficacy of injectable carbapenems for respiratory infections caused by Streptococcus pneumoniae and Haemophilus influenzae with Monte Carlo simulation]. BIPM, IPM/CS, MEPM, PAPM/BP
45  2007 [Investigation of Streptococcus pneumoniae and Haemophilus influenzae isolated from pediatric outpatients nationwide with a respiratory tract infection at the first consultation (2002-2003)--with special reference to the results of nasopharyngeal culture in pediatric patients with no previous history of antibacterial drug administration]. BLNAR
46  2006 Orally active carbapenem antibiotics I. Antibacterial and pharmacokinetic potential of 2-phenyl and 2-thienylcarbapenems. BLNAR
47  2006 Proinflammatory activation of Toll-like receptor-2 during exposure of penicillin-resistant Streptococcus pneumoniae to beta-lactam antibiotics. PBP, PSSP, TLR2
48  2006 Study of nasopharyngeal bacterial flora. Second report. Variations in nasopharyngeal bacterial flora in children aged 6 years or younger when administered antimicrobial agents. Part 1. AOM, AURTI, BLNAR, CDTR-PI, PCR
49  2006 Synthesis and SAR study of novel 7-(pyridinium-3-yl)-carbonyl imidazo[5,1-b]thiazol-2-yl carbapenems. BLNAR, MRSA
50  2005 4-Alkyl and 4,4'-dialkyl 1,2-bis(4-chlorophenyl)pyrazolidine-3,5-dione derivatives as new inhibitors of bacterial cell wall biosynthesis. ---
51  2005 Comparison of activities of beta-lactam antibiotics against Streptococcus pneumoniae with recombinant penicillin-binding protein genes from a penicillin-resistant strain. MICs
52  2005 Daptomycin: a novel agent for Gram-positive infections. CNS, GISA, MRSA, VRE
53  2005 In vitro and in vivo antibacterial activities of CS-023 (RO4908463), a novel parenteral carbapenem. MRSA
54  2005 [In vitro combined effect of meropenem and various antimicrobial agents against beta-lactamase-nonproducing ampicillin-resistant Haemophilus influenzae and penicillin-resistant Streptococcus pneumoniae]. BLNAR, CTX, MEPM
55  2005 [Study on PBPs genes of penicillin-resistant Streptococcus pneumonia in Zhejiang province]. PBPs
56  2004 Detection of penicillin-binding protein 2b gene alteration in Streptococcus mitis by polymerase chain reaction. CCL, MICs, PBP2b, PCR, SSN
57  2004 Efficacy and tolerability of moxifloxacin in the treatment of acute bacterial sinusitis caused by penicillin-resistant Streptococcus pneumoniae: a pooled analysis. ABS, MICs, PSSP
58  2004 In vitro activities of ME1036 (CP5609), a novel parenteral carbapenem, against methicillin-resistant staphylococci. MRSA
59  2004 Therapeutic efficacy of meropenem for treatment of experimental penicillin-resistant pneumococcal meningitis. CSF
60  2004 [An adult case of bacterial meningitis caused by penicillin-resistant streptococcus pneumoniae]. ABPC, CTX, PAPM/BP, VCM
61  2004 [Antimicrobial prophylaxis in surgery]. MRSA
62  2004 [The history of the development and changes of quinolone antibacterial agents]. CPFX, ENX, FRLX, GFLX, LFLX, LVFX, MRCNS, MRSA, NA, NFLX, OFLX, PPA, PULX, PZFX, SPFX, TFLX, VRE
63  2003 DNA binding ligands targeting drug-resistant bacteria: structure, activity, and pharmacology. MRSA, VRE
64  2003 In vitro activity of S-3578, a new broad-spectrum cephalosporin active against methicillin-resistant staphylococci. MRSA
65  2003 In vitro antimicrobial activity of oxidized regenerated cellulose against antibiotic-resistant microorganisms. MRSA, MRSE, ORC, VRE
66  2003 Low rates of antimicrobial resistance in respiratory pathogens from a pediatric population in north-eastern Italy. ---
67  2003 Nocathiacins, new thiazolyl peptide antibiotics from Nocardia sp. I. Taxonomy, fermentation and biological activities. MREF, MRSA
68  2003 Prevalence and clinical significance of community-acquired penicillin-resistant pneumococcal pneumonia in Thailand. NCCLS
69  2003 Synthesis and structure-activity relationships of 5-amino-6-fluoro-1-[(1R,2S)-2-fluorocyclopropan-1-yl]-8-methylquinolonecarboxylic acid antibacterials having fluorinated 7-[(3R)-3-(1-aminocyclopropan-1-yl)pyrrolidin-1-yl] substituents. CPFX, GFLX, MFLX, MRSA, VRE
70  2003 [PRSP (penicillin-resistant Streptococcus pneumoniae)]. ---
71  2003 [Surveillance on gram-positive bacteria isolated from patients with hospital acquired infections or community acquired infections]. AREF, CAI, HAI, MRSA, MRSE
72  2003 [The utility of the Pneumonia PORT prediction rule for evaluating the severity of community-acquired pneumonia in Japan. The relationship between disease severity and drug-resistant Streptococcus pneumoniae]. CAP, PISP, PSSP
73  2002 A case of retropharyngeal abscess caused by penicillin-resistant Streptococcus pneumoniae. ---
74  2002 Clinical aspects and cost of invasive Streptococcus pneumoniae infections in children: resistant vs. susceptible strains. CAD, PSSP
75  2002 Evaluation of T-3811ME (BMS-284756), a new des-F(6)-quinolone, for treatment of meningitis caused by penicillin-resistant Streptococcus pneumoniae in rabbits. AUC, CSF
76  2002 Non-fluorinated quinolones (NFQs): new antibacterials with unique properties against quinolone-resistant gram-positive pathogens. i.v, MRSA, NFQs
77  2002 Orally active cephalosporins. Part 4: synthesis, structure--activity relationships and oral absorption of novel 3-(4-pyrazolylmethylthio)cephalosporins with various C-7 side chains. ---
78  2002 Outcome of treatment of respiratory tract infections due to Streptococcus pneumoniae, including drug-resistant strains, with pharmacokinetically enhanced amoxycillin/clavulanate. ABS, AECB, AMX/CA, CAP
79  2002 [A case of pediatric recurrent acute mastoiditis caused by penicillin-resistant Streptococcus pneumonia complicated by primary immunodeficiency]. CVID
80  2001 Activity of non-fluorinated quinolones (NFQs) against quinolone-resistant Escherichia coli and Streptococcus pneumoniae. NFQs
81  2001 Bacteriologic and clinical efficacy of high dose amoxicillin/clavulanate in children with acute otitis media. AOM
82  2001 Geographic, demographic, and seasonal differences in penicillin-resistant Streptococcus pneumoniae in Baltimore. ---
83  2001 Measuring and interpreting associations between antibiotic use and penicillin resistance in Streptococcus pneumoniae. PSSP
84  2001 Risk factors for penicillin-resistant Streptococcus pneumoniae acquisition in patients in Bangkok. PSSP
85  2001 The prevalence and clonal diversity of penicillin-resistant Streptococcus pneumoniae in Kuwait. PFGE, REP-PCR
86  2001 [Beta-lactam and macrolide resistance in Streptococcus pneumoniae]. PBPs
87  2001 [In vitro and in vivo activities of panipenem against penicillin-resistant Streptococcus pneumoniae]. CTRX, CZOP, IPM/CS, MEPM, PAPM/BP, PISP, PSSP, VCM
88  2001 [The latest trend of PRSP infection]. ---
89  2000 Comparative In vitro activities of daptomycin and vancomycin against resistant gram-positive pathogens. MRSA, VREF
90  2000 Pneumococcal Pneumonia. ---
91  2000 Therapeutic effects of parenteral beta-lactam antibiotics on experimental otitis media caused by penicillin-resistant Streptococcus pneumoniae in guinea-pigs. ---
92  2000 [Drug-resistant bacteria in clinical situations]. ESBLs, MDRMT, MRSA, VRE
93  2000 [Infections with drug resistant bacteria and their treatment methods--PRSP infections]. ---
94  2000 [Report of questionnaire survey for methicillin-resistant Staphylococcus aureus and penicillin-resistant Streptococcus pneumoniae in the Kinki District]. MRSA, PISP
95  1999 Development of a new experimental model of penicillin-resistant Streptococcus pneumoniae pneumonia and amoxicillin treatment by reproducing human pharmacokinetics. ---
96  1999 Efficacy of beta-lactam antibiotics combined with gentamicin against penicillin-resistant pneumococcal pneumonia in CBA/J mice. ---
97  1999 In vitro and in vivo antimicrobial activities of T-3811ME, a novel des-F(6)-quinolone. MIC90s
98  1999 Molecular epidemiological survey of penicillin-resistant Streptococcus pneumoniae from Asia, Europe, and North America. PBP
99  1999 Treatment of pneumococcal pneumonia: the case for penicillin G. MICs
100  1999 [Report of questionnaire survey for methicillin-resistant Staphylococcus aureus and penicillin-resistant Streptococcus pneumoniae in the Kinki District]. GM, MINO, MRSA, ST, VCM